



## Xencor to Participate in Upcoming Investor Conferences

September 25, 2018

MONROVIA, Calif., Sept. 25, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will participate in three upcoming conferences:

- **2018 Cantor Global Healthcare Conference**  
**Date:** Tuesday, October 2, 2018  
**Location:** New York, NY  
**Presentation Time:** 10:55 a.m. ET
- **Leerink Partners Roundtable Series: Rare Disease & Oncology**  
**Date:** Wednesday, October 3, 2018  
**Location:** New York, NY  
**Presentation Time:** 10:00 a.m. ET
- **BTIG Biotech Conference**  
**Date:** Thursday, October 25, 2018  
**Location:** New York, NY  
Management will be available for one-on-one meetings.

Live webcasts of both the 2018 Cantor Global Healthcare Conference and the Leerink Partners Roundtable Series: Rare Disease & Oncology presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 90 days following the presentations.

### About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 12 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb@5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb@7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb@14045 in Phase 1 development for acute myeloid leukemia; XmAb@13676 in Phase 1 development for B-cell malignancies; XmAb@18087 in Phase 1 development for the treatment of neuroendocrine tumors and gastrointestinal stromal tumors; XmAb@20717 in Phase 1 development for the treatment of advanced solid tumors, and XmAb@22841, XmAb@23104 and XmAb@24306 in pre-clinical development for the treatment of multiple cancers. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, CSL, Alexion and Boehringer Ingelheim. For more information, please visit [www.xencor.com](http://www.xencor.com).



SOURCE Xencor, Inc.

Investor Contact: John Kuch, Senior Vice President, Finance and Chief Financial Officer, Xencor, Tel: 626-737-8013, [jkuch@xencor.com](mailto:jkuch@xencor.com); Corporate Communications Contact: Jason I. Spark, Canale Communications for Xencor, Tel: 619-849-6005, [jason@canalecomm.com](mailto:jason@canalecomm.com)